Regenerative Medicine Market Background
Data drawn from Regenerative Medicine Market
The global regenerative medicine market size was valued at USD 27.29 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.27% from 2021 to 2027.
Currently, North America dominates the global market with a revenue share of more than 45% in 2020.
The Asian market is predicted to experience a higher CAGR going forward, due to the expansion of infrastructure and facilities to accelerate stem cell research in emerging economies.
Currently, the highest volume of regenerative medical care patients in the region go to countries with less stringent regulatory environments such as China, India, and Thailand.
Progress in Japan was achieved through the Ministry of Health, Labor and Welfare approvals around Regenerative Medicine law, which propelled the clinical development of regenerative and cell-based therapies.
Medical Tourism
According to Smart Traveler, over 15,000 Australians travel for medical tourism with stem cell therapy being among the top services sought.
In Indonesia, the Ministry of Health estimates between 1,000,000 and 2,000,000 Indonesians yearly go abroad for medical care.
According to SingMedic, a company that helps Indonesians to obtain treatment overseas, approximately 31% of these patients (~450,000) are seeking cancer treatment each year.
​
This is driven by a large domestic market where the prevalence of cancer among Indonesians is 1.74% (~4 million) per the 2018 Indonesian health profile (Riskesdas 2018).
In the Asian Region, thousands of patients are receiving regenerative care from clinics that charge exorbitant prices for unproven treatment due to inefficient regulation controls around quality of care in countries like China, India and Thailand.
More
Info
The Sanur SEZ is designed to attract 4–8% of the Indonesian outbound medical tourism market (80–60 thousand people) by 2030 in addition to in-bound medical tourists from other countries.
​
Simplr International has brought together leading Japanese Regenerative Health Care specialists, Indonesian health consulting experts, support from both Indonesian and Australian Governments, and a team of leading industry specialists.
​
Full transparency and a high level of integrity is how we operate, and seek the same in our investors.
As a leading regenerative medicine specialist facility, the aim of the clinic will be to provide state-of-the-art stem cell therapy for cancer treatment, with services supported by the world-class oncology center at Bali International Hospital, also to be located in the Special Economic Zone.